

2019

Immunomodulation with Human Umbilical Cord Blood Stem Cells Ameliorates Ischemic Brain Injury – A Brain Transcriptome Profiling Analysis

Maple L. Shiao
University of Minnesota

Ce Yuan
University of Minnesota

Andrew T. Crane
University of Minnesota

Joseph P. Voth
University of Minnesota

Mario Juliano
University of Minnesota

Follow this and additional works at: https://digitalcommons.usf.edu/nbr_facpub
See next page for additional authors

 Part of the [Neurosurgery Commons](#)

Scholar Commons Citation

Shiao, Maple L.; Yuan, Ce; Crane, Andrew T.; Voth, Joseph P.; Juliano, Mario; Hocum Stone, Laura L.; Nan, Zhenghong; Zhang, Ying; Kuzmin-Nichols, Nicole; Sanberg, Paul R.; Grande, Andrew W.; and Low, Walter C., "Immunomodulation with Human Umbilical Cord Blood Stem Cells Ameliorates Ischemic Brain Injury – A Brain Transcriptome Profiling Analysis" (2019). *Neurosurgery and Brain Repair Faculty Publications*. 27. https://digitalcommons.usf.edu/nbr_facpub/27

This Article is brought to you for free and open access by the Neurosurgery and Brain Repair at Digital Commons @ University of South Florida. It has been accepted for inclusion in Neurosurgery and Brain Repair Faculty Publications by an authorized administrator of Digital Commons @ University of South Florida. For more information, please contact scholarcommons@usf.edu.

Authors

Maple L. Shiao, Ce Yuan, Andrew T. Crane, Joseph P. Voth, Mario Juliano, Laura L. Hocum Stone, Zhenghong Nan, Ying Zhang, Nicole Kuzmin-Nichols, Paul R. Sanberg, Andrew W. Grande, and Walter C. Low

Immunomodulation with Human Umbilical Cord Blood Stem Cells Ameliorates Ischemic Brain Injury – A Brain Transcriptome Profiling Analysis

Cell Transplantation
2019, Vol. 28(7) 864–873
© The Author(s) 2019
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/0963689719836763
journals.sagepub.com/home/ctj


Maple L. Shiao^{1,*}, Ce Yuan^{2,*}, Andrew T. Crane¹, Joseph P. Voth¹,
Mario Juliano¹, Laura L. Hocum Stone^{1,3}, Zhenghong Nan¹,
Ying Zhang⁴, Nicole Kuzmin-Nichols⁵, Paul R. Sanberg⁶,
Andrew W. Grande^{1,3,7,**}, and Walter C. Low^{1,2,3,7,**}

Abstract

Our group previously demonstrated that administration of a CD34-negative fraction of human non-hematopoietic umbilical cord blood stem cells (UCBSC) 48 h after ischemic injury could reduce infarct volume by 50% as well as significantly ameliorate neurological deficits. In the present study, we explored possible mechanisms of action using next generation RNA sequencing to analyze the brain transcriptome profiles in rats with ischemic brain injury following UCBSC therapy. Two days after ischemic injury, rats were treated with UCBSC. Five days after administration, total brain mRNA was then extracted for RNAseq analysis using Illumina HiSeq 2000. We found 275 genes that were significantly differentially expressed after ischemic injury compared with control brains. Following UCBSC treatment, 220 of the 275 differentially expressed genes returned to normal levels. Detailed analysis of these altered transcripts revealed that the vast majority were associated with activation of the immune system following cerebral ischemia which were normalized following UCBSC therapy. Major alterations in gene expression profiles after ischemia include blood-brain-barrier breakdown, cytokine production, and immune cell infiltration. These results suggest that UCBSC protect the brain following ischemic injury by down regulating the aberrant activation of innate and adaptive immune responses.

Keywords

stem cells, human umbilical cord blood, stroke, immunomodulation, neuroinflammation, macrophage, microglia

Introduction

Each year, over 750,000 individuals in the United States suffer a stroke, making it a leading cause of morbidity and mortality. The primary treatment for stroke is administration of tissue plasminogen activator (tPA). Unfortunately, the vast majority of stroke victims are unable to reach hospital emergency rooms within the 3- to 5-h time-window following stroke onset required for effective tPA therapy. Therapies that expand the time window of treatment are therefore much needed.

We previously isolated a CD34-negative population of non-hematopoietic umbilical cord blood stem cells (UCBSC) within human umbilical cord blood that is highly expandable and exhibit stem cell-like properties¹. Systemic administration of UCBSC 48 h after ischemic brain injury resulted in a significant reduction in infarct volume and an

¹ Department of Neurosurgery, University of Minnesota, Minneapolis, USA

² Graduate Program in Bioinformatics and Computational Biology, University of Minnesota, Minneapolis, USA

³ Graduate Program in Neuroscience, University of Minnesota, Minneapolis, USA

⁴ Minnesota Supercomputing Institute, University of Minnesota, Minneapolis, USA

⁵ Saneron CCEL Therapeutics Inc, Tampa, USA

⁶ Center for Brain Repair and Department of Neurosurgery, Morsani College of Medicine, University of South Florida, Tampa, USA

⁷ Stem Cell Institute, University of Minnesota, Minneapolis, USA

*Both the authors are co-first authors in this article.

**Both the authors are co-senior authors of this article.

Submitted: May 21, 2018. Revised: January 15, 2019. Accepted: February 8, 2019.

Corresponding Author:

Walter C. Low, Department. of Neurosurgery, Stem Cell Institute, University of Minnesota Minneapolis, MN 55455, USA.
Email: lowwalt@umn.edu



amelioration in neurological severity score as well as limb placement function in the rat MCAO model of stroke^{1,2}. Interestingly, very few UCBSC were observed in the brain 28 days post transplantation, suggesting a neurotrophic or anti-inflammatory function of UCBSC therapy. Indeed, flow cytometry analysis revealed a reduction in infiltrating immune cells following ischemic stroke and UCBSC treatment². The use of stem cells derived from the umbilical cord blood/matrix have garnered recent attention for their immunomodulatory and neuroprotective properties^{3–6}. Animal and human studies of ischemic brain injuries demonstrate that the activation of the immune system and inflammation are important pathological processes following ischemia^{7–9}.

In the present study, we investigated the immunological mechanisms by which UCBSC exert their neuroprotective effects, focusing on blood-brain-barrier (BBB)/extracellular matrix (ECM) function, immune cell infiltration, and secondary apoptosis. We postulate that UCBSC therapy modulates the immune system to reduce the infiltration of immune cells into the brain following ischemic injury, thereby reducing secondary injury. To address this issue we performed RNA sequencing (RNAseq) to study the brain transcriptome change in rats following ischemic injury and after the systemic administration of UCBSC.

Materials and Methods

Animal Model of Acute Focal Ischemic Stroke

To induce acute focal transient ischemic stroke, adult Sprague Dawley rats (175.0 ± 25.0 g; Groups: Normal, MCAO, MCAO+UCBSC; *n* = 5/group) were anesthetized with a cocktail (0.85 ml/kg) of ketamine (75 mg/ml Ketaject; Phoenix Pharmaceuticals, Burlingame, CA, USA) and xylazine (10 mg/ml Xyla-ject; Phoenix Pharmaceuticals) intramuscularly. Each rat's head was stabilized in a Kopf head holder on Stereotaxic Frame (Tujunga, CA, USA) in a supine position after the fur of the neck area was shaved and sterilized. A midline incision in the skin of the neck was made to expose subdermal structures. The right common carotid artery was exposed and traced distally to its bifurcation, the superficial branch of which is the external carotid artery (ECA). The right ECA was cauterized and cut to be able to introduce the thread occluder for the temporary ligation. The right internal carotid artery (rICA) has an extracranial branch before it enters the cranium—the pterygopalatine artery—which was temporarily ligated for a complete ischemic lesion. The rECA was cut at its distal stem so that a silicon-coated surgical thread could be inserted into its lumen. The thread was inserted into the bifurcation, up into rICA, to occlude the middle cerebral artery (MCAO). The occluder is kept in place for 1 h before removal. The open arteries were then cauterized, the wound closed, and the animal monitored until fully sternal and recovered. All procedures were approved by the IACUC at the University of Minnesota (Protocol Number: 133-31062A). Considerations

for the ethical use of animals in this study as well as alternatives to the use of animals were submitted to IACUC prior to final approval and authorization.

UCBSC Culture

CD34 negative UCBSC were isolated and grown as previously described¹. Briefly, umbilical cord blood was collected after delivery and, within 4 h, mononuclear cells were separated by centrifugation at 500 × *g* for 30 min in a Ficoll-hypaque density gradient (1.077 g/cm³) (Sigma, St. Louis, MO, USA). The cells were then grown in Dulbecco's modified Eagle medium DMEM (Invitrogen, Waltham, MA, USA) / MCDB-201 (Sigma) mix with 10% fetal bovine serum (Invitrogen), 10⁻⁴ M of L-ascorbic-acid-2-PO₄ (Sigma), 10⁻⁹ M of dexamethasone (Sigma), insulin-transferrin-selenium media supplement (Sigma), 1 mg/mL of linoleic acid/bovine serum albumin (Sigma) and 10 ng/ml of epidermal growth factor (R&D Systems, Minneapolis, MN, USA) and recombinant human basic fibroblast growth factor (R&D Systems).

Stem Cell Delivery

Two days post-MCAO, animals in the treatment group were injected with 1 million UCBSC suspended in 500 μL of sterile saline delivered via saphenous vein under isoflurane anesthesia. Immunosuppressant drugs (e.g. Cyclosporine A) were not administered as we have previously observed beneficial effects of UCBSC therapy in the absence of immunosuppressive agents¹⁰.

Behavioral Testing

Neurological function was assessed by a neurological severity score (NSS) test¹¹ on day 2 and day 7 post-MCAO. The NSS test consists of eight subtests evaluating motor and sensorimotor function of the animals' limbs. Left and right side limbs were each scored as either 2 (normal function), 1 (impaired function), or 0 (unable to perform). The scores from these subtests were tallied for the right side and left side limbs and analyzed using a Student's *t*-test.

Tissue Processing and RNA Sequencing

Immediately following NSS testing on day 7, the rats were deeply anesthetized with ketamine (150 mg/kg). We chose to do the RNAseq at 7 days because we wished to compare the transcriptome results with our previous flow cytometry study². Rats were then transcardially perfused with phosphate buffer saline and the hemisphere ipsilateral to the MCAO was isolated. Total RNA was extracted from all 15 brains using the RNeasy Plus Mini Kit (Qiagen, Germantown, MA, USA) according to manufacturer's instructions. Each sample was obtained in triplicate (one animal had duplicate samples only) for a total of 44 total RNA samples submitted for sequencing.

RNA samples were analyzed at the University of Minnesota Biomedical Genomics Center. Briefly, total RNA samples were quantified using the RiboGreen fluorometry assay and RNA integrity was checked using capillary electrophoresis (Agilent BioAnalyzer 2100; Agilent, Santa Clara, CA, USA). Libraries were generated from 1 μ g of total RNA. Polyadenylated coding mRNA in each sample was isolated and reverse transcribed using random primers. The resulting paired-end cDNA libraries were subsequently sequenced using the HiSeq 2000 (Illumina, San Diego, CA, USA). For each sample, at least 10 million paired-end reads of 50 base pairs were performed in four lanes.

Bioinformatics Analysis

FASTQ files for each sample were first combined before analysis. Raw sequences were analyzed using a customized pipeline (gopher-pipelines; <https://bitbucket.org/jgarbe/gopher-pipelines/overview>) developed and maintained by the Minnesota Supercomputing Institute. Briefly, quality controls were performed on each FASTQ files using FastQC (v0.11.5) before and after adapter trimming with Trimmomatic (v0.33). Post-trimming sequences were aligned to *Rattus norvegicus* reference genome using HISAT2 (v2.0.2). Transcript abundance was then estimated using subread (v1.4.6)^{12,13}. Pathway analysis of differentially expressed genes was performed by functionally annotating the genes, performing an overrepresentation enrichment test using BiNGO package, and visualizing using Cytoscape¹⁴.

Read counts generated by subread were filtered to include genes with counts per million >5 and subsequently analyzed in R¹⁵. The remaining reads were then normalized and log transformed using *edgeR*. Heat maps were generated using the log transformed values with *pheatmap* package. Hierarchical clustering was performed using Euclidean distances and average linkage clustering method. Principle component analysis (PCA) was performed in R using *prcomp* and visualized using *ggplot2* and *rgl* packages. Immune cell subtype analysis was performed using CIBERSORT (<https://cibersort.stanford.edu/>) following the recommended settings for RNA-Seq data. Two-sided Student's *t*-test was performed to assess the CIBERSORT results¹⁶. All *P*-values are listed in the supplementary files. *P*-values ≤ 0.05 were considered as significant differences.

Results

UCBSC Therapy Ameliorates Behavioral Deficits

Two days after MCAO, all animals exhibited sensorimotor deficits assessed by the NSS test. At this time-point, no significant differences were observed between the two treatment groups (Fig 1). Five days after the systemic administration of UCBSC (7 days post-MCAO), a significant improvement in NSS score was observed in ischemic rats treated with UCBSC, relative to untreated ischemic rats (*t*-test *P* = 0.046).

UCBSC Therapy Globally Diminishes the Immunological Response to Stroke

To gain insights into the mechanisms of action underlying UCBSC therapy in ischemic brain injury, we compared the brain transcriptome in normal, MCAO, and MCAO+UCBSC rats. After initial filtering, a total of 12,788 genes were used for differential expression (DE) analysis. PCA shows the MCAO group is clearly clustered separate from both control and MCAO+UCBSC treatment groups (Fig 1A–C). Plotting DE genes of MCAO or MCAO+UCBSC against gene expression levels of the normal brain further depicts a separation of untreated MCAO transcripts (Fig 2A). Relative to the control brain, the MCAO group had 275 DE genes (4 downregulated, 271 upregulated; Fig 2B; Supplementary Table ST1). After UCBSC treatment, 220 of the 275 genes that were initially altered following MCAO returned to normal levels (Fig 2B; Supplementary Table ST2). Among the 55 genes that remain DE, 42 show a trend shifting towards normal levels (Fig 2B). Among the 4 genes initially downregulated after MCAO, only the *Pdcd5* gene returned to normal levels after UCBSC treatment. Relative to control rats, treatment of ischemic rats with UCBSC results in normalization of the gene expression profile (Supplementary Table ST3). A total of 101 genes were DE (19 downregulated, 82 upregulated) between the two groups. We then used gene ontology enrichment analysis to analyze alterations to the function of these DE genes. The downregulated genes showed no significant pathway enrichment; however, the pathways of the 220 upregulated genes showed enrichment in numerous pathways related to immune system processes, and immune cell activations suggesting UCBSC treatment effectively diminishes immune response caused by MCAO (Supplementary Fig 1; Supplementary Table ST4).

UCBSC Therapy Normalizes Gene Transcripts Related to BBB and ECM Function

Because the breakdown of the extracellular matrix (ECM) and blood-brain-barrier (BBB) allows immune cells to penetrate into the brain following ischemic injury, we specifically investigated genes related to the BBB functions (Fig 3A; Supplementary Table ST5, 6). We also identified genes associated with extracellular matrix (GO:0031012) from the Gene Ontology Consortium (Fig 3B). The results show most genes associated with BBB and ECM were upregulated following MCAO treatment and normalized by treatment with UCBSC (Supplementary Table ST5, 6).

UCBSC Therapy Reduces Apoptotic Gene Transcripts

To assess if UCBSC can reduce cell death after MCAO, we investigated genes related to apoptosis. We identified genes associated with the regulation of apoptotic process (GO:0042981) from the Gene Ontology Consortium. The results show most genes associated with apoptosis were




Fig 1. UCBSB therapy ameliorates neurological deficits induced by MCAO. (A) The Neurological Severity Scores (NSS) were similar for the two groups of animals 2 days post MCAO but prior to the UCBSB therapy. Five days after UCBSB cell therapy (day 7 after MCAO), NSS scores improved significantly in the UCBSB treated group (t -test $P = 0.046$). (B, C, and D) PCA of RNA-seq data show MCAO-treated samples cluster separately from Normal and MCAO+UCBSB groups.

upregulated following MCAO treatment and normalized with UCBSB therapy (Fig 3C; Supplementary Table ST7).

UCBSB Therapy Normalizes Gene Transcripts Related to Cytokine Production

Cytokines are involved in stroke-induced cerebral inflammation. We identified genes associated with regulation of cytokine production (GO:0001817) from the Gene Ontology Consortium plotted as a heatmap (Fig 3D). Results demonstrate many genes associated with pro-inflammatory cytokines were upregulated following MCAO treatment and normalized by UCBSB (Supplementary Table ST8).

UCBSB Therapy Returns Immune Cell Subtypes to Normal Levels

We next investigated the immune cell infiltration after MCAO using CIBERSORT with the Im22 immune gene

signature set (Fig 4). The absolute score estimated by CIBERSORT show significantly increased immune cell infiltration after MCAO (0.97 vs. 0.47; MCAO vs. Control; two-sided t -test $P = 0.039$). An intermediate effect of UCBSB was observed where treated animals were not statistically significant from MCAO (0.97 vs. 0.60; MCAO vs. MCAO+UCBSB; $P = 0.126$) nor controls (0.47 vs. 0.60; Control vs. MCAO+UCBSB; $P = 0.160$).

Deeper analysis among the subtypes of immune cell and inflammatory cell within the CIBERSORT identified a significant increase in transcripts specific for monocytes, resting dendritic cells, CD8- and naive CD4-T cells, as well as a decrease in transcripts specific for M2 macrophages following MCAO, relative to controls. Gene transcripts associated with neutrophils (Fig 5A), natural killer cells (Fig 5B), microglia/macrophages (Fig 5C), B-cells (Fig 5D), mast cells (Fig 5E), CD4 T-cells (Fig 5F) and regulatory T-cells (Fig 5G) were significantly increased after MCAO, and UCBSB therapy reversed these transcripts back to normal levels.




Fig 2. Gene expression analysis following MCAO and UCBSC treatment. (A) Scatter plot of significantly DE genes that return to normal expression levels after UCBSC treatment. Black dotted line represents expression levels of transcripts from normal brain. Red dots are expression levels of transcripts from MCAO group. Aqua colored circles are expression levels of transcripts after UCBSC treatment. X-axis indicates log₁₀ counts per million (cpm) level from normal brain. Y-axis represents expression levels for the same transcript from MCAO group or UCBSC group. (B) Gene expression patterns following MCAO and UCBSC treatment.

Discussion

Consistent with our previously published reports², the data presented here suggest UCBSC is an effective treatment for ischemic stroke and acts through modulation of the immune system. We hypothesize that a breakdown of the BBB and ECM results in increased infiltration of immune cells, leading to secondary damage at the site of infarction. We observed that UCBSC treatment rescued sensorimotor deficits following stroke and systematically normalized gene expression alterations caused by MCAO. Our results suggest the underlying mechanism of UCBSC treatment in protecting the brain following a stroke is through dampening the immune response and immune cell infiltration. These changes are consistent with reports by other investigations on ischemic brain injury^{17–20}.

Stroke and BBB/ECM Function

The initial pathophysiological processes that permit the penetration of immune cells into the brain parenchyma following ischemic injury is the breakdown of the BBB and ECM. Cell adhesion molecules engage immune cells and initiate their penetration across the BBB²¹. After cerebral ischemia, we observed an upregulation in the expression of ICAM1, which is part of the immunoglobulin superfamily, and is involved in many processes including inflammation, immune responses and intracellular signaling. Immediately following ischemia, ICAM1 expression is localized to

capillary endothelium of intra-parenchymal blood vessels, but expression is increased in leukocytes in the weeks following^{22–24}. Interestingly, cell-surface expression levels of ICAM1 correlated with infiltration of CD4 + or effector memory T-cells²⁵, suggesting that modulation of ICAM1 expression by UCBSC may play a role in the observed reduction in infiltrating immune cells. Preclinical treatment of ischemia with anti-ICAM1 antibodies reduced edema and infarct size²⁶, although this effect was not translated into the clinic²⁷.

Matrix metalloproteinase (MMP) enzymes are responsible for the breakdown of the ECM by degrading tight junctions and basal lamina proteins, leading to immune cell infiltration²⁸. We observed an upregulation of transcripts of several MMPs (including -2, -8, -12, -14, and -19) at 7 days post-ischemia that was normalized with UCBSC treatment. In rodent models of cerebral ischemia, elevation of MMP-2, MMP-8, and MMP-14 have been observed^{29–31}. Interestingly, an increase in expression of MMP regulator Timp1 was observed in untreated ischemic animals, suggesting that BBB damage has peaked and vascular remodeling may begin³¹. Further investigation is warranted to determine if UCBSC treatment inhibits BBB breakdown or mediates rapid vascular repair.

Cytokine/Chemokine Modulation

Through gene ontology, we identified DE genes in our dataset associated with cytokine and chemokine production.




Fig 3. Heatmap of (A) BBB, (B) ECM, (C) apoptosis, and (D) cytokine associated genes. The expression pattern of these genes return to normal expression levels after UCBSC treatment. Red indicates relative increase in expression and blue indicates relative decrease in expression.

Specifically, we observed an upregulation of Tgf- β 1 and many interleukin receptors in ischemic rats 7 days following MCAO. The increased expression of Tgf- β 1 is likely driven by the increase in macrophages and microglia at the site of infarction, as previous studies have demonstrated increased colocalization of Tgf- β 1 signaling in Cd68 + cells³². Other cytokine specific DE genes we observed to be upregulated following MCAO include Ccl2, Hmx1, TLR2, Serpine1, and C3ar1. Similarly, increase expression of chemokines Pycard, Tlr4, Il4ra, Tlr7, and Csf1r were increased in untreated MCAO rats. These cytokines and chemokines are likely to be upregulated due to the migration of microglia at

the site of infarction³³. Given the complex interactions and kinetics between the many pro- and anti-inflammatory cytokines and their receptors following injury, it is difficult to determine the possible mechanisms at a single time-point. However, possible sites of action may include the spleen, cervical lymph nodes, and other lymphoid organs where UCBSC may interact with immune cells.

Modulation of the Immune Cell Infiltration

Using the CIBERSORT analysis package, we were able to quantify transcripts associated to individual immune-cell




Fig 4. CIBERSORT analysis of control, MCAO, and UCBSC treatment. The relative percentage of different immune cell types were deconvoluted from the RNA-seq data using CIBERSORT.

subtypes. Similar to our previous study interrogating inflammation through flow cytometry within the ischemic hemisphere, we observed increased transcripts associated with innate immune system cells – NK cells, neutrophils, monocytes/macrophages, and resting dendritic cells; and cells associated with the adaptive immune system – CD8-T cells and naive CD4 + T-cells, and B-cells. In addition, a decrease in pro-recovery M2 macrophages was observed. The activation of the innate immune system triggered immediately after ischemic stroke and is manifested by the mobilization of NK cells, neutrophils, resident macrophages, and microglia infiltrating the infarct zone within minutes after ischemia^{34,35}. In untreated MCAO rats we observed increased expression in genes (including *Trem2*, *Csf1*, and *Irf8*) that have been associated with activation and proliferation of microglia^{33,36}.

Infiltration of peripheral immune cells into the site of infarction also plays an important role in the outcome of ischemia. Within 1 h, antigen presenting dendritic cells infiltrate the ischemic brain^{37–39}. In the ischemic brain hemisphere, a 20-fold elevation of dendritic cells was observed

at 3 days post-ischemia, which remained elevated at 12-fold normal levels on day 7³⁷. In the normal brain, CD4 + and CD8 + cytotoxic T cell lymphocytes cells are present at low levels; however, after ischemic injury, there is a dramatic influx of CD4 + cells, which can activate resident brain microglia and upregulate endothelial cell adhesion molecules, increasing BBB permeability^{40–42}. Perhaps through UCBSC treatment following MCAO, a normalization of the pro-recovery M2 macrophages/microglia is able to reduce inflammation, thereby reducing infiltration of peripheral adaptive immune cells. Further work is needed to determine the kinetics of inflammation following UCBSC therapy.

Ischemic Cascade

In addition to neuronal death via necrosis or immune cell infiltration, secondary apoptosis occurs in the oxygen-deprived penumbra surrounding the initial infarct zone²⁰. We observed that transcripts related to apoptosis were upregulated following ischemic injury, specifically, *Scamp2*, *Cebpa*, *Shc1*, *Sipa1*, *Tep1*, *Ucp2*, *Dap*, *Plp2*, *Ccnb1*, and *Sla*. Furthermore, treatment with UCBSC seemed to restore these transcripts to control levels.

A previous study showed Cyclin-B1 (*Ccnb1*) to be upregulated and cytotoxic following ischemia through excitotoxicity⁴³. Other cell cycle-related genes we found to be upregulated following ischemia were *Cebpa*, *Acer2*, and *Tep1*. The increased expression of these genes suggests that cell proliferation mechanisms are upregulated following ischemia. This upregulation may result from glial, immune cell, or neuronal proliferation, but this question needs to be pursued further.

Reactive oxygen species (ROS) expression in the peri-infarct region has been shown to induce apoptosis following ischemia²⁰. Inhibition of *SHC1* following ischemia in rats has decreased infarct size, as well as penumbra-associated apoptosis, likely through a decrease in ROS creation^{44,45}. In our study, we found that UCBSC lower the expression of *SHC1* to non-infarct control levels, suggesting these UCBSC may decrease ROS production, thus preventing apoptosis induction.

Conclusion

In summary, we provide a systems approach to study the cellular mechanisms underlying the neuroprotective effects of UCBSC treatment for ischemic brain injury. Our transcriptomics analysis reveal UCBSC are able to reduce upregulation of transcripts associated with BBB permeability, thereby reducing infiltration and activation of immune cells, which we believe is responsible for the downregulation of apoptotic related genes. These data further suggest that the UCBSC therapy is modulating the microglia/macrophage population to promote a pro-recovery M2 phenotype. This modulation of the immune system occurs even when the UCBSC are administered 2 days after the ischemic injury,




Fig 5. Box plot showing RNA expression levels change of (A) Neutrophil, (B) Natural Killer cell, (C) Macrophage, (D) B-cell, (E) Mast cell, (F) T-cell, and (G) Regulatory T-cell related gene transcripts after MCAO (Red) and UCBSC treatment (Green). * denotes statistical significance between the three groups $P < 0.05$ (edgeR, false-discovery-rate adjusted).

significantly expanding the therapeutic window currently available for tPA treatment. This study provides insights into understanding the cellular mechanisms of stroke and its treatment with UCBSC. The cellular mechanisms underlying the therapeutic benefit of these stem cells provides a basis for future clinical studies evaluating the safety and efficacy of these cells in treating patients with ischemic brain injury.

Acknowledgment

We thank Kyle Schaible for editorial assistance.

Ethical Approval

This study was approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Minnesota.

Statement of Human and Animal Rights

All experimental procedures involving animals were conducted in accordance with the IACUC guidelines at the University of Minnesota.

Statement of Informed Consent

There are no human subjects in this article and informed consent is not applicable.

Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: P.R. Sanberg and W.C. Low are founder and consultant, respectively, of Saneron CCEL Therapeutics, Inc., and are inventors on patents related to cord blood. N. Kuzmin-Nichols is an inventor on patents related to cord blood. PRS is the co-editor-in-chief of Cell Transplantation. Neither PRS nor any member of the editorial office or editorial board affiliated the authors' institutions was involved with the review process and/or decision making of this manuscript. The remaining authors declare no conflict of interest.

Funding

The author(s) disclosed receipt of the following financial support for the research and/or authorship of this article: This work was supported in part by funds from NIH grant R41-NS056626, and from Suzanne M. Schwarz, and Walter and Ginger Bailey. Ce Yuan is supported by the MnDrive-UMII Graduate Fellowship.

Supplemental Material

Supplemental material for this article is available online.

Reference

- Xiao J, Nan Z, Motooka Y, Low WC. Transplantation of a novel cell line population of umbilical cord blood stem cells ameliorates neurological deficits associated with ischemic brain injury. *Stem Cells Dev.* 2005;14(6):722–733.
- Hocum Stone LL, Xiao F, Rotschafer J, Nan Z, Juliano M, Sanberg CD, Sanberg PR, Kuzmin-Nichols N, Grande A, Cheeran MC, Low WC. Amelioration of ischemic brain injury in rats with human umbilical cord blood stem cells: mechanisms of action. *Cell Transplant.* 2016;25(8):1473–1488.
- Donders R, Vanheusden M, Bogie JFJ, Ravanidis S, Thewissen K, Stinissen P, Gyselaers W, Hendriks JJA, Hellings N. Human Wharton's jelly-derived stem cells display immunomodulatory properties and transiently improve rat experimental autoimmune encephalomyelitis. *Cell Transplant.* 2015;24(10):2077–2098.
- Lin W, Hsuan YCY, Lin MT, Kuo TW, Lin CH, Su YC, Niu KC, Chang CP, Lin HJ. Human umbilical cord mesenchymal stem cells preserve adult newborn neurons and reduce neurological injury after cerebral ischemia by reducing the number of hypertrophic microglia/macrophages. *Cell Transplant.* 2017;26(11):1798–1810.
- Wu KJ, Yu SJ, Chiang CW, Cho KH, Lee YW, Yen BL, Kuo LW, Wang Y. Transplantation of human placenta-derived multipotent stem cells reduces ischemic brain injury in adult rats. *Cell Transplant.* 2015;24(3):459–470.
- Shahaduzzaman MD, Mehta V, Golden JE, Rowe DD, Green S, Tadinada R, Foran EA, Sanberg PR, Pennypacker KR, Willing AE. Human umbilical cord blood cells induce neuroprotective change in gene expression profile in neurons after ischemia through activation of Akt pathway. *Cell Transplant.* 2015;24(4):721–735.
- Schilling M, Besselmann M, Leonhard C, Mueller M, Ringelstein EB, Kiefer R. Microglial activation precedes and predominates over macrophage infiltration in transient focal cerebral ischemia: a study in green fluorescent protein transgenic bone marrow chimeric mice. *Exp Neurol.* 2003;183(1):25–33.
- Gan Y, Liu Q, Wu W, Yin JX, Bai XF, Shen R, Wang Y, Chen J, La Cava A, Poursine-Laurent J, Yokoyama W, Shi FD. Ischemic neurons recruit natural killer cells that accelerate brain infarction. *Proc Natl Acad Sci U S A.* 2014;111(7):2704–2709.
- Brait VH, Arumugam TV, Drummond GR, Sobey CG. Importance of T lymphocytes in brain injury, immunodeficiency, and recovery after cerebral ischemia. *J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab.* 2012;32(4):598–611.
- Chen Y, Ye L, Zhong J, Li X, Yan C, Chandler MP, Calvin S, Xiao F, Negia M, Low WC, Zhang J, Yu X. The structural basis of functional improvement in response to human umbilical cord blood stem cell transplantation in hearts with postinfarct LV remodeling. *Cell Transplant.* 2015;24(6):971–983.
- Schaar KL, Brenneman MM, Savitz SI. Functional assessments in the rodent stroke model. *Exp Transl Stroke Med.* 2010;2:13.
- Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. *Nat Methods.* 2015;12(4):357–360.
- Liao Y, Smyth GK, Shi W. Featurecounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics.* 2014;30(7):923–930.
- Maere S, Heymans K, Kuiper M. BiNGO: a Cytoscape plugin to assess overrepresentation of Gene Ontology categories in biological networks. *Bioinformatics.* 2015;21(16):3448–3449.
- Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics.* 2010;26(1):139–140.
- Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. *Nat Methods.* 2015;12(5):453.
- Schilling M, Strecker JK, Schäbitz WR, Ringelstein EB, Kiefer R. Effects of monocyte chemoattractant protein 1 on blood-borne cell recruitment after transient focal cerebral ischemia in mice. *Neuroscience.* 2009;161(3):806–812.
- Möller K, Boltze J, Pösel C, Seeger J, Stahl T, Wagner DC. Sterile inflammation after permanent distal MCA occlusion in hypertensive rats. *J Cereb Blood Flow Metab.* 2014;34(2):307–315.

19. Cox-Limpens KEM, Gavilanes AWD, Zimmermann LJI, Vles JSH. Endogenous brain protection: what the cerebral transcriptome teaches us. *Brain Res.* 2014;1564:85–100.
20. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. *Nat Med.* 2011;17(7):796.
21. Frijns CJM, Kappelle LJ. Inflammatory cell adhesion molecules in ischemic cerebrovascular disease. *Stroke.* 2002;33(8):2115–2122.
22. Ramos-Cejudo J, Gutiérrez-Fernández M, Rodríguez-Frutos B, Expósito Alcaide M, Sánchez-Cabo F, Dopazo A, Díez-Tejedor E. Spatial and temporal gene expression differences in core and periinfarct areas in experimental stroke: a microarray analysis. *Plos One.* 2012;7(12):e52121.
23. Deddens LH, van Tilborg GAF, van der Marel K, Hunt H, van der Toorn A, Viergever MA, de Vries HE, Dijkhuizen RM. In Vivo molecular MRI of ICAM-1 expression on endothelium and leukocytes from subacute to chronic stages after experimental stroke. *Transl Stroke Res.* 2017;8(5):440–448.
24. Choi C, Oh SH, Noh JE, Jeong YW, Kim S, Ko JJ, Kim OJ, Song J. Attenuation of Postischemic Genomic Alteration by Mesenchymal Stem Cells: a Microarray Study. *Mol Cells.* 2016;39(4):337–344.
25. Abadier M, Haghayegh Jahromi N, Cardoso Alves L, Boscacci R, Vestweber D, Barnum S, Deutsch U, Engelhardt B, Lyck R. Cell surface levels of endothelial ICAM-1 influence the transcellular or paracellular T-cell diapedesis across the blood-brain barrier. *Eur J Immunol.* 2015;45(4):1043–1058.
26. Matsuo Y, Onodera H, Shiga Y, Shozuhara H, Ninomiya M, Kihara T, Tamatani T, Miyasaka M, Kogure K. Role of cell adhesion molecules in brain injury after transient middle cerebral artery occlusion in the rat. *Brain Res.* 1994;656(2):344–352.
27. Enlimomab Acute Stroke Trial Investigators. Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. *Neurology.* 2001;57(8):1428–1434.
28. Lakhan SE, Kirchgessner A, Tepper D, Leonard A. Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke. *Front Neurol.* 2013;4:32.
29. Planas AM, Solé S, Justicia C. Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after transient focal cerebral ischemia. *Neurobiol Dis.* 2001;8(5):834–846.
30. Buga AM, Scholz CJ, Kumar S, Herndon JG, Alexandru D, Cojocaru GR, Dandekar T, Popa-Wagner A. Identification of new therapeutic targets by genome-wide analysis of gene expression in the ipsilateral cortex of aged rats after stroke. *Plos One.* 2012;7(12):e50985.
31. Hirono J, Sanaki H, Kitada K, Sada H, Suzuki A, Lie LK, Segi-Nishida E, Nakagawa K, Hasegawa H. Expression of tissue inhibitor of metalloproteinases and matrix metalloproteinases in the ischemic brain of photothrombosis model mice. *Neuroreport.* 2018;29(3):174–180.
32. Doyle KP, Cekanaviciute E, Mamer LE, Buckwalter MS. TGF β signaling in the brain increases with aging and signals to astrocytes and innate immune cells in the weeks after stroke. *J Neuroinflammation.* 2010;7:62.
33. Khan A, Ju F, Xie W, Tariq Hafeez M, Cheng X, Yang Z, Zhu L, Li T, Zhang S. Transcriptomic analysis reveals differential activation of microglial genes after ischemic stroke in mice. *Neuroscience.* 2017;348:212–227.
34. Chiba T, Umegaki K. Pivotal roles of monocytes/macrophages in stroke. *Mediators Inflamm.* 2013;2013:759103.
35. Parada E, Egea J, Buendia I, Negro P, Cunha AC, Cardoso S, Soares MP, López MG. The microglial α 7-acetylcholine nicotinic receptor is a key element in promoting neuroprotection by inducing heme oxygenase-1 via nuclear factor erythroid-2-related factor 2. *Antioxid Redox Signal.* 2013;19(11):1135–1148.
36. Kierdorf K, Prinz M. Factors regulating microglia activation. *Front Cell Neurosci.* 2013;7:44.
37. Gelderblom M, Leypoldt F, Steinbach K, Behrens D, Choe CU, Siler DA, Arumugam TV, Orthey E, Gerloff C, Tolosa E, Magnus T. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. *Stroke.* 2009;40(5):1849–1857.
38. Kostulas N, Li HL, Xiao BG, Huang YM, Kostulas V, Link H. Dendritic cells are present in ischemic brain after permanent middle cerebral artery occlusion in the rat. *Stroke.* 2002;33(4):1129–1134.
39. Yilmaz G, Granger DN. Leukocyte recruitment and ischemic brain injury. *Neuromolecular Med.* 2010;12(2):193–204.
40. Gidday JM, Gasche YG, Copin JC, Shah AR, Perez RS, Shapiro SD, Chan PH, Park TS. Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. *Am J Physiol Heart Circ Physiol.* 2005;289(2):H558–H568.
41. Kleinschnitz C, Kraft P, Dreykluft A, Hagedorn I, Göbel K, Schuhmann MK, Langhauser F, Helluy X, Schwarz T, Bittner S, Mayer CT, et al. Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature. *Blood.* 2013;121(4):679–691.
42. Brea D, Agulla J, Rodríguez-Yáñez M, Barral D, Ramos-Cabrer P, Campos F, Almeida A, Dávalos A, Castillo J. Regulatory T cells modulate inflammation and reduce infarct volume in experimental brain ischaemia. *J Cell Mol Med.* 2014;18(8):1571–1579.
43. Maestre C, Delgado-Esteban M, Gomez-Sanchez JC, Bolaños JP, Almeida A. Cdk5 phosphorylates Cdh1 and modulates cyclin B1 stability in excitotoxicity. *EMBO J.* 2008;27(20):2736–2745.
44. Spescha RD, Shi Y, Wegener S, Keller S, Weber B, Wyss MM, Lauinger N, Tabatabai G, Paneni F, Cosentino F, Hock C, Weller M, Nitsch RM, Lüscher TF, Camici GG. Deletion of the ageing gene p66Shc reduces early stroke size following ischaemia/reperfusion brain injury. *Eur Heart J.* 2013;34(2):96–103.
45. Spescha RD, Klohs J, Semerano A, Giacalone G, Derungs RS, Reiner MF, Rodríguez Gutierrez D, Mendez-Carmona N, Glanzmann M, Savarese G, Kränkel N, et al. Post-ischaemic silencing of p66 Shc reduces ischaemia/reperfusion brain injury and its expression correlates to clinical outcome in stroke. *Eur Heart J.* 2015;36(25):1590–1600.